Comparison Of Intrathecal Levobupivacaine Plus Nalbuphine Versus Levobupivacaine Plus Fentanyl For Lower Limb Orthopedic Surgery A Prospective Randomized Study - NIL

开始日期2626-04-01

申办/合作机构

State of Gujarat

CTRI/2026/08/116288

/ Not yet recruitingN/AIIT

A Randomised Controlled Trial Of Intra Venous Nalbuphine-Propofol Versus Fentanyl-Propofol In Short Surgical Procedures Under General Anesthesia With Proseal Laryngeal Mask Airway Insertion. - nil

开始日期2026-10-05

申办/合作机构

Stanley Medical College

NCT07837492

/ Not yet recruiting临床4期IIT

Ultrasound-Guided Ilioinguinal-Iliohypogastric Nerve Block Following Spinal Anesthesia Comparing Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Unilateral Inguinal Hernia Repair: A Prospective, Randomized, Double-Blind Controlled Study

This study evaluates and compares the pain-relieving efficacy and safety of adding either dexmedetomidine or nalbuphine to bupivacaine in an ultrasound-guided ilioinguinal-iliohypogastric nerve block for patients undergoing elective unilateral inguinal hernia repair under spinal anesthesia.
While spinal anesthesia provides effective surgical anesthesia, postoperative pain often increases as the block recedes. Supplementing spinal anesthesia with an ultrasound-guided peripheral nerve block targeting the ilioinguinal and iliohypogastric nerves provides localized pain relief. Adding adjuvant medications to the local anesthetic may extend the duration of pain control and reduce systemic analgesic requirements.
Participants are randomly allocated to one of three groups:
* Control Group: Receives bupivacaine with normal saline.
* Nalbuphine Group: Receives bupivacaine combined with nalbuphine.
* Dexmedetomidine Group: Receives bupivacaine combined with dexmedetomidine.
The primary objective is to assess the duration of analgesia by measuring the time from the regression of spinal sensory anesthesia until the first request for rescue pain medication. Secondary objectives include evaluating total 24-hour pain medication consumption, postoperative pain scores, vital signs, sedation scores, patient satisfaction, and side effects.

开始日期2026-10-01

申办/合作机构

Assiut University

100 项与盐酸纳布啡相关的临床结果

登录后查看更多信息

100 项与盐酸纳布啡相关的转化医学

登录后查看更多信息

100 项与盐酸纳布啡相关的专利（医药）

登录后查看更多信息

1,573

项与盐酸纳布啡相关的文献（医药）

2027-01-01·TALANTA

Machine learning-assisted photoelectrochemical aptasensor for nalbuphine monitoring using a BiOBr/SrWO4 S-scheme heterojunction

Article

作者: Liu, Jingyang ; Wang, YuanYuan ; Xiao, Yangjie ; Zhu, Ying ; Ma, Yan

Precise therapeutic drug monitoring is essential for optimizing nalbuphine treatment in uremic pruritus, yet rapid and sensitive analytical tools suitable for clinical application remain limited. Herein, we report a machine learning-guided photoelectrochemical (PEC) aptasensor for nalbuphine detection based on a BiOBr/SrWO₄ S-scheme heterojunction. Clinical data from 102 peritoneal dialysis patients were first analyzed using seven machine learning algorithms to identify determinants of therapeutic response. Gradient Boosting exhibited the best predictive performance, with an accuracy of 84.6%, a response recall of 83.3%, and an AUC of 0.868 on the independent test set, and nalbuphine dose emerged as the most influential variable, establishing the clinical need for accurate drug monitoring. Guided by this finding, a signal-on PEC aptasensor was constructed by integrating a BiOBr/SrWO₄ heterojunction photoactive interface with an NH₂-modified ssDNA aptamer for selective nalbuphine recognition. The optimized BiOBr/SrWO₄-40% composite displayed enhanced visible-light harvesting, suppressed charge recombination, and accelerated interfacial charge transfer. Ultraviolet photoelectron spectroscopy and density functional theory calculations further verified the S-scheme charge-transfer pathway and the built-in electric field-driven carrier separation mechanism. Under optimal conditions, the aptasensor exhibited a linear response toward nalbuphine from 0.01 to 1.2 μg mL^-1 with a limit of detection (LOD) of 3.5 ng mL^-1, along with good selectivity, stability, and reproducibility. In spiked serum samples, recoveries ranged from 96.05% to 99.59% with relative standard deviations below 5%. This work provides a clinically oriented strategy for integrating machine learning with PEC biosensing and offers a promising platform for personalized therapeutic drug monitoring.

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Modulation of mu-opioid pathway for the treatment of pruritus: a systematic review of 1,146 patients

Review

作者: Abu Suleiman, Amro ; Ahmed, Khalid M. A. ; Alnajdawi, Alaa I. ; Moustafa, Ahmed R. A. ; Horton, Emma ; Ahmed, Ahmed M. ; Abdulkader, Dina

BACKGROUND:

Pruritus is a debilitating symptom and conventional therapies often provide incomplete relief. The μ-opioid receptor (MOR) pathway is a key regulator of itch, and μ-pathway-modulating agents are increasingly used off-label for refractory pruritus.

AIM:

This systematic review evaluates the efficacy, safety, and real-world use of μ-opioid pathway modulators for pruritus of dermatologic and systemic origin.

METHODS:

Following PRISMA guidelines (PROSPERO CRD420251207101), a comprehensive search of four databases identified 3,274 records, of which 69 studies met inclusion criteria, comprising 14 randomized controlled trials (RCTs; n = 795) and 55 non-randomized studies (n = 351). Owing to substantial clinical and methodological heterogeneity, findings were narratively synthesized.

RESULTS:

Five RCTs evaluated dermatologic conditions, including atopic dermatitis, prurigo nodularis, chronic urticaria, and lichen planopilaris, while nine RCTs assessed systemic pruritus, predominantly cholestatic and uremic pruritus. RCTs investigated oral or topical naltrexone, intravenous naloxone, nalmefene, and extended-release nalbuphine, with most demonstrating clinically meaningful reductions in pruritus intensity using validated itch scales. Non-randomized studies reported improvement across a wide range of dermatologic and systemic conditions, with adverse events generally mild and well tolerated.

CONCLUSIONS:

Overall, μ-opioid pathway modulators show promising efficacy with acceptable short-term safety across diverse pruritic conditions, although larger high-quality RCTs are required to define optimal dosing and support clinical translation.

2026-12-01·Current Pain and Headache Reports

Adjunct Medications for Single-Injection Pediatric Regional Blocks: Implications for Peripheral Nerve Blocks

Review

作者: Jha, Sachin Sunny

PURPOSE OF REVIEW:

Single-injection peripheral nerve blocks (PNBs) provide excellent perioperative analgesia in children but are limited by finite duration. Pediatric populations were excluded from the major adult adjunct reviews. This narrative review synthesizes the evidence for adjuncts added to local anesthetics for single-injection PNBs and caudal blocks in patients aged 0 to 18 years, including dexamethasone, dexmedetomidine, clonidine, conventional opioids, buprenorphine, magnesium sulfate, midazolam, ketamine, neostigmine, tramadol, nalbuphine, and epinephrine.

RECENT FINDINGS:

Across 58 studies, dexmedetomidine (0.5 to 1 mcg/kg) and dexamethasone (0.1 mg/kg perineural) were the best-supported agents, each roughly doubling analgesic duration with acceptable safety. Two network meta-analyses ranked neostigmine highest for caudal duration, but its postoperative nausea and vomiting burden limits use. Clonidine has the longest safety record. Ketamine and midazolam show robust caudal efficacy but unresolved neurotoxicity concerns. Nalbuphine and buprenorphine are promising but under-studied. Tramadol carries pediatric regulatory restrictions, while epinephrine and conventional opioids add little. Dexmedetomidine and dexamethasone are the preferred adjuncts in pediatric regional anesthesia. Adult evidence should not be extrapolated directly given developmental pharmacology and pediatric-specific safety considerations. Prospective trials in true pediatric PNBs and pediatric rebound-pain studies remain the critical evidence gaps.

360

项与盐酸纳布啡相关的新闻（医药）

2026-11-02

·BioSpace

Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio ™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2026. Conference Call and Webcast To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events . Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio ™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life. RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially. The FDA has conditionally accepted Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn . Investor Contact Jonathan Carlson Trevi Therapeutics, Inc. (203) 654 3286 IR@trevitx.com Media Contact Rosalia Scampoli 914-815-1465 rscampoli@marketcompr.com

财报临床结果

2026-11-01

·Pharm-Patent

近几年恒瑞医药、海思科、绿叶制药、人福医药、恩华药业在麻醉镇痛、精神神经领域产品研发管线对比（十六）（V2，2026.11.1更新）

（十四）罗哌卡因-RF-16001（HL-003） 1、研究机构：宜昌人福药业有限责任公司、北京辉粒科技有限公司、百仕康（杭州）生物医药有限公司、辉粒药业（苏州）有限公司 2、靶点：Sodium channel 3、剂型及给药途径：注射用微球; 注射给药 4、适应症及进展适应症进展最新进展日期术后疼痛 III期 2026-09-16 疼痛 II期 2024-08-01 5、专利布局公开（公告）号专利主题发明名称申请日法律状态 CN109010307B 制剂载麻醉镇痛药缓释微球、其制备方法及其应用 2018-08-02 CN116669717A 制剂长效原位成型/胶凝组合物 2021-08-17 实质审查 6、研究历程 2026年09月10日，由辉粒药业（苏州）有限公司在中国大陆开展临床二期试验，用于治疗术后疼痛。（CTR20263503） 2026年03月31日，由北京辉粒科技有限公司、宜昌人福药业有限责任公司和百仕康（杭州）生物医药有限公司在中国大陆开展临床三期试验，用于治疗术后疼痛。（CTR20252700） 2025年10月21日，由辉粒药业（苏州）有限公司在中国大陆开展临床一期试验，用于治疗术后疼痛。（CTR20253917） 2024年01月05日，由北京辉粒科技有限公司、宜昌人福药业有限责任公司和百仕康（杭州）生物医药有限公司在中国大陆开展临床二期试验，用于治疗术后疼痛。（CTR20233870; CTR20263503; CTR20242858; CTR20253476） 2022年07月01日，由北京辉粒科技有限公司、宜昌人福药业有限责任公司和百仕康（杭州）生物医药有限公司在中国大陆开展临床一期试验，用于治疗术后疼痛。（CTR20253917; CTR20221476） 2021年11月01日，由宜昌人福药业有限责任公司开展临床前研究试验。 7、临床试验登记号试验标题试验药适应症原始适应症申办/合作机构试验状态试验分期开始日期完成日期国家/地区 NCT07872826 To Evaluate the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty (THA) in a Multicenter, Randomized, Double-blind, Parallel, Positive and Placebo-controlled Phase Ⅲ Clinical Trial RF-16001 镇痛 | 术后疼痛 Pain After Abdominal Surgery 中南大学湘雅三医院 | 国家自然科学基金委员会 Enrolling by invitation 临床3期 2026-10-10 2027-10-31 中国 CTR20263503 评价注射用RF16001单次神经阻滞给药用于全膝关节置换术后镇痛的药代动力学特征以及有效性、安全性的随机、双盲、阳性对照的Ib/Ⅱ期研究 RF-16001 (注射剂) 镇痛术后镇痛辉粒药业（苏州）有限公司 | 宜昌人福药业有限责任公司 Not yet recruiting 临床2期 - - 中国 CTR20253917 评价注射用RF16001在中国健康受试者中单次神经阻滞给药后的安全性、药代动力学、药效学Ⅰa期临床研究 RF-16001 (注射剂) 术后疼痛术后镇痛辉粒药业（苏州）有限公司 | 宜昌人福药业有限责任公司 Completed 临床1期 2025-10-16 2025-12-05(国内) 中国 CTR20253476 评价注射用RF16001局部浸润用于全髋关节置换术后镇痛的疗效、安全性、药代动力学的多中心、随机、双盲、平行、阳性及安慰剂对照、剂量探索Ⅱ期临床试验 RF-16001 (注射剂, 局部浸润注射) 术后疼痛术后镇痛北京辉粒科技有限公司 | 百仕康（杭州）生物医药有限公司 | 宜昌人福药业有限责任公司 Completed 临床2期 2025-10-14 2026-03-15(国内) 中国 ChiCTR2500107498 To evaluate the efficacy, safety and pharmacokinetics of local infiltration of RF16001 for injection for analgesia after total hip arthroplasty (THA) in a multicenter, randomized, double-blind, parallel, positive and placebo-controlled, dose-finding phase Ⅱ clinical trial RF-16001 镇痛 Pain 中南大学湘雅三医院 Not yet recruiting 临床2期 2025-08-15 2026-08-14 中国 CTR20252700 评价注射用罗哌卡因缓释微球（RF16001）局部浸润用于痔切除术后镇痛的有效性、安全性的多中心、随机、双盲、平行、阳性及安慰剂对照III期临床试验 RF-16001 (注射剂) 术后疼痛术后镇痛北京辉粒科技有限公司 | 百仕康（杭州）生物医药有限公司 | 宜昌人福药业有限责任公司 Completed 临床3期 2026-03-30 2026-09-01(国内) 中国 CTR20250293 注射用罗哌卡因缓释微球在健康志愿者中的药代动力学对比研究 RF-16001 (注射剂) 术后疼痛术后镇痛北京辉粒科技有限公司 | 百仕康（杭州）生物医药有限公司 | 宜昌人福药业有限责任公司 Completed 临床1期 2025-02-06 2025-04-13(国内) 中国（十五）右美托咪定透皮贴剂（3-Day Dexmedetomidine Patch、TPU-006） 1、研究机构：人福医药集团股份公司 2、靶点：ADRA2 3、剂型及给药途径：贴剂; 皮肤给药 4、适应症及进展适应症进展最新进展日期术后疼痛 II期 2024-06-20 5、专利布局公开（公告）号专利主题发明名称申请日法律状态 CN117750949B 制剂右美托咪定经皮组合物、透皮贴剂及其制备方法和应用 2022-08-22 CN117582424A 制剂右美托咪定经皮组合物、透皮贴剂及其制备方法和应用 2023-08-15 实质审查（十六）对乙酰氨基酚+羟考酮缓释片 1、研究机构：宜昌人福药业有限责任公司 2、靶点：COX、OPR 3、剂型及给药途径：缓释/控释片; 口服给药 4、适应症及进展适应症进展最新进展日期疼痛申请上市 2026-03-12 （十七）氢可酮+对乙酰氨基酚（Hydrocodone+Acetaminophen） 1、研究机构：宜昌人福药业有限责任公司 2、靶点：COX、OPR 3、剂型及给药途径：缓释/控释片; 口服给药 4、适应症及进展适应症进展最新进展日期疼痛 III期 2024-11-29 （十八）纳布啡(新适应症)（Nalbuphine、RF-20043） 1、研究机构：宜昌人福药业有限责任公司 2、靶点：KOR、DOR、MOR 3、剂型及给药途径：注射剂; 注射给药 4、适应症及进展适应症进展最新进展日期疼痛申请上市 2026-01-12 麻醉 I期 2024-06-15 （十九）舒芬太尼透皮贴 1、研究机构：宜昌人福药业有限责任公司 2、靶点：OPR 3、剂型及给药途径：贴剂; 皮肤给药 4、适应症及进展适应症进展最新进展日期癌痛 II期 2025-06-25 慢性疼痛 II期 2024-09-06 疼痛 I期 2025-06-15 5、专利布局公开（公告）号专利主题发明名称申请日法律状态 CN110693857B 制剂一种舒芬太尼透皮贴剂及其制备方法 2019-10-17 CN111419826B 制剂一种舒芬太尼透皮给药的药物组合物及其制备方法和应用 2018-12-21 （二十）舒芬太尼(新适应症) 1、研究机构：宜昌人福药业有限责任公司 2、靶点：OPR 3、剂型及给药途径：注射剂; 注射给药 4、适应症及进展适应症进展最新进展日期疼痛 II期 2026-04-07 （二十一）RFUS-301 1、研究机构：宜昌人福药业有限责任公司 2、剂型及给药途径：注射剂; 注射给药 3、适应症及进展适应症进展最新进展日期术后疼痛批准临床 2025-02-26 （二十二）艾司氯胺酮（新适应症） 1、研究机构：宜昌人福药业有限责任公司 2、靶点：GRIN 3、剂型及给药途径：注射剂; 注射给药 4、适应症及进展适应症进展最新进展日期抑郁症 II期 2026-09-02 （二十三）咪达唑仑鼻喷雾剂（midazolam nasal spray、USL261、咪哒唑仑、咪唑安定、咪唑二氮卓、咪唑仑、Versed） 1、研究机构：宜昌人福药业有限责任公司、中国人民解放军军事医学科学院毒物药物研究所 2、靶点：GABRA 3、剂型及给药途径：鼻用气雾剂/喷雾剂/粉雾剂; 鼻腔给药 4、适应症及进展适应症进展最新进展日期惊厥性癫痫持续状态 I期 2024-06-15 （二十四）艾司氯胺酮口颊粘膜溶液 1、研究机构：宜昌人福药业有限责任公司 2、靶点：GRIN 3、剂型及给药途径：口颊粘膜溶液; 口腔黏膜给药 4、适应症及进展适应症进展最新进展日期抑郁症、自杀意念批准临床 2026-06-23 5、专利布局公开（公告）号专利主题发明名称申请日法律状态 CN116942647A 制剂艾司氯胺酮液体制剂及其用途 2023-04-19 实质审查 CN116942646A 制剂 R-氯胺酮液体制剂及其用途 2023-04-19 实质审查 CN116942648A 制剂艾司氯胺酮液体制剂及其用途 2023-04-19 实质审查 CN118986868A 制剂氯胺酮液体制剂及其用途 2024-05-15 实质审查（二十五）R-氯胺酮(宜昌人福) 1、研究机构：宜昌人福药业有限责任公司 2、靶点：CHRM、AMPAR、GRIN 3、剂型及给药途径：注射剂; 注射给药 4、适应症及进展适应症进展最新进展日期抑郁症批准临床 2026-05-12

临床2期临床3期临床1期

2026-10-30

·赢家之路

科技股暴跌，别手痒痒，还在半山腰，华海药业，人福医药三季报分析

A股三大指数今日集体回调，截止收盘，沪指跌1.44%，收报3599.02点，失守3600点；深证成指跌2.73%，收报10833.78点；创业板指跌4.13%，收报2413.63点；科创50报收1160.84点，大跌5.48％。沪深两市成交额1.67万亿，较上个交易日放量1179亿。全市场超4600只个股下跌，涨停个股数量方面，今日共计49股涨停。热门股继续暴跌，杠杆爆仓，踩踏，韭菜被踩的体无完肤，遍体鳞伤，市场哀鸿遍野，鬼哭狼嚎。　　行业板块多数收跌，白酒、医疗服务、航运港口板块涨幅居前，影视院线、游戏、传媒、广告营销、软件开发、通信设备、半导体板块跌幅居前。主要指数本月集体收跌，整体呈现缩量下跌的走势，双创指数月跌超23%，创业板指较今年6月的历史高点跌幅超44%，深成指、中证500、中证2000均跌超15%。沪深两市超4500只个股月线收阴，本月个股涨跌幅中位数超12%。从板块来看，红利股逆势走强，建设银行、工商银行、中国银行、中信银行、陕西煤业创历史新高，中国神华续创近19年新高，中国石油创18年新高。下跌方面，算力硬件股本月跌幅居前，CPO、PCB方向集体走弱，源杰科技、长光华芯、广合科技跌超50%；锂电龙头股宁德时代月线三连阴，月跌近20%，股价自2026年5月7日创出的历史高点回落超50%。科技股暴跌还在半山腰，现在才是业绩业绩增速放缓，下一步就是产能过剩，价格战，业绩下滑，大幅度下滑，大部分亏损，股价打回原形，许多可能在价格战中淘汰出局，其实今天的光伏行业隆基绿能就是科创板前世今生，隆基绿能从十几块钱上涨，最高92元，今天股价11元，还在没完没了的亏损过程中，跌破个位数也算大概率，所以科技股没有护城河，没有门槛，昨天美股盘后英特尔跳楼了，暴跌23％，今天晚上美股科技股可能继续下跌，A股科技股也算雪上加霜，看看人家美股科技股才二十三倍市盈率，长鑫科技也才二十倍左右市盈率，韩国三星，海力士也才五六倍市盈率，咱们大A科技股搞到200倍市盈率，现在暴跌腰斩还是100多倍市盈率，再腰斩两次才基本合理，矫枉过正，上涨过头，下跌也可能过头，跌到个位数市盈率也算非常有可能的。曾经热门的光伏，白酒，新能源。中国石油，哪一个都跌的让韭菜怀疑人生，这一次科技股也变化不一样。错过了科技股上涨，千万别半山腰接飞刀，多砍了手指头的，抱团一旦瓦解，没有三五年不会再有行情的，沉舟侧畔千帆过，病树前头万木春。看看现在的五粮液，和隆基绿能就知道以后的科技股是说明样子了。指数规律也算今年常识问题，不会不一样的。自选股银行四大行今天没有继续大涨，购房者银行兴业银行，招商银行，平安银行强势上涨，医药股也算蠢蠢欲动，华海药业，乐普医疗，科伦药业一度上涨，尾盘回落，保险股港股继续大涨，A股保险股小幅度调整，尾盘收盘没有拉拉队拉升，前几次都是尾盘拉高我卖出，今天买入的没有卖出，等待下一个交易日。高股息中远海控大涨7.02%，创出今年新高。关注的上港集团也算是业绩大增股价大涨，躺着赚钱的生意有时候业绩也能大涨。华海药业2026三季度业绩分析一、核心数据；前三季度累计营收：74.30亿元，同比+15.86%归母净利润：10.60亿元，同比+178.61%扣非净利润：7.02亿元，同比+160.00%。经营现金流：15.28亿元，同比+134.2%，现金流修复明显 Q3单季（亮点：同比扭亏）营收：25.12亿元，同比+32.75%归母净利润：2.89亿元（去年同期-0.29亿），扣非净利润：2.76亿元（去年同期-0.93亿）。二、业务拆解（增长驱动）原料药（基本盘）：新品持续上量、海外客户拓展，新品增速高，是扣非改善核心；多个专利到期品种进入放量周期，收入弹性大。国内制剂：集采接续窗口期新增12个中标品种，存量保份额、新品贡献增量，国内制剂收入稳步抬升。美国制剂：精细化运营、控费提量，前三季度实现扭亏，是本轮最大边际改善点，摆脱过去多年美国业务持续亏损拖累利润的局面。创新药管线（长期看点）：HB0034（瑞西奇拜单抗，IL-36R单抗）7月获批上市，是国内首个自研泛脓疱型银屑病生物药；HB0017（IL-17A单抗）报产，HB0025双抗Ⅲ期推进，管线从仿制药向生物创新药兑现。一次性收益（区分主业）：缬沙坦仲裁补偿、美国关税退回、子公司股权转让收益增厚归母利润；归母增速显著高于扣非，这部分属于非经常性、不可持续收益。三、核心亮点； ✅ 美国制剂扭亏，历史包袱缓解，盈利结构优化 ✅ 原料药新品放量，不再单纯依赖老品种价格战 ✅ 创新药实现商业化落地，估值逻辑增加创新药兑现预期 ✅ 现金流大幅改善，资产负债表压力减轻四、主要风险集采降价压力：国内制剂持续集采，中标后价格下行，压制长期毛利率原料药周期竞争：专利到期品种放量后，同行扎堆入局，价格容易快速下滑海外监管+汇率：FDA/EMA检查、贸易壁垒、美元波动，出口业务扰动大创新药商业化风险：HB0034刚上市，竞争激烈，放量、销售回报存在不确定性；后续管线临床、审批失败风险一次性收益不可持续：仲裁、退税、股权处置收益很难重复，后续归母增速会向扣非收敛。五、小结与跟踪重点 Q3是基本面拐点季度：美国制剂扭亏+原料药新品放量共同推动主业盈利修复，叠加一次性收益放大利润增速；但要分清：扣非代表主业真实改善，高归母增速含有一次性红利。后续重点跟踪： ✅ 美国制剂单季度毛利率、持续盈利稳定性 ✅ 原料药新品报价、竞争格局 ✅ HB0034上市后销售放量数据 ✅ 国内集采续标、海外FDA检查、汇率。六，股东人数减少，筹码集中度提升；三季度81072户，半年报83272，一季度89340 年初82636户，股东人数连续乐观季度减少，筹码集中度提升。综合聊聊；华海药业集采大赢家，中标越来越多，量变到质变，传统仿制药也亏损企稳回升，厚积薄发，创新药也算有了希望，等待授权过程中。值得继续期待。股东人数，筹码集中度提升，万事俱备只欠东风，就等待对外授权引爆股价了。 ST人福（600079 ，人福医药）2026三季报业绩简析一、核心财务数据；前三季度累计营收：184.12亿元，同比+2.96%，归母净利润：24.15亿元，同比+43.01%，扣非归母净利润：17.97亿元，同比+7.87%。核心特征：归母利润大幅高于扣非，利润弹性来自非经常性收益，主业增长偏稳健。 Q3单季营收：63.52亿元，同比+9.15%归母净利润：10.85亿元，同比+103.27%，扣非净利润：5.08亿元，同比-5.10%。重点：Q3扣非同比小幅下滑，翻倍的归母增速主要靠资产处置、投资收益等一次性收益，主业单季盈利承压。二、业务拆解宜昌人福（麻醉镇痛，基本盘）国内精麻管制壁垒极高，瑞芬太尼、舒芬太尼、氢吗啡酮等核心品种暂不纳入集采，国内份额长期领先；磷丙泊酚、纳布啡等新品种持续放量，海外多国获批（德国、英国等），打开出口空间。麻醉板块毛利率极高，是公司现金流基石。葛店人福（甾体激素+两性健康）原料制剂一体化，黄体酮、芦比前列酮等陆续拿到FDA批文，海外仿制药持续申报；两性健康产品线稳步推进，产能搬迁完成后释放产能。 Epic Pharma（美国仿制药）美国本土制剂平台，历史上减值、亏损拖累业绩；当前逐步出清低效品种，关税退回、老品种调价阶段性增厚利润，但海外监管、FDA检查、竞争降价风险持续存在。新疆维药特色民族药，多个独家医保品种，渠道稳步拓展，作为稳定第二曲线。医药商业低毛利配送业务，拉低整体综合毛利率，属于配套业务，不是利润来源。归核聚焦（战略主线）持续剥离非核心资产、瘦身减负，招商局入主后优化融资、降利息，资产负债率下行，财务压力减轻；同时推进定增，投向麻药、创新药研发。三、亮点 ✅ 麻醉赛道壁垒强，核心品种避开集采，现金流稳定，是A股稀缺的精麻龙头。 ✅ 招商局赋能，融资成本下降、资产结构持续优化，历史减值风险逐步出清。 ✅ 海外申报提速，多款麻药、甾体药拿到欧美批文，国际化兑现。 ✅ 资产处置带来大额收益，短期利润弹性大。四、核心风险（重点）利润结构分化风险：Q3扣非转负、归母大增，一次性收益不可持续，后续归母增速大概率回落至扣非水平，容易出现增速断崖。政策风险：精麻药品监管严格，未来如果政策调整、医保控费传导至麻药，会冲击高毛利底盘；其他普通制剂面临集采降价。美国业务不确定性：Epic竞争激烈、FDA核查、汇率波动，容易反复扰动利润。创新兑现偏慢：管线以仿制药改良型为主，重磅1类新药兑现周期长，短期很难接力麻药。 ST标识：仍存在历史遗留事项，需要持续跟踪摘帽进展。五、小结与跟踪重点； Q3属于一次性收益驱动的高利润季度，主业盈利边际走弱。它的核心价值是麻醉赛道的政策壁垒，适合看长做长；但不能把本次归母翻倍当成主业高增长。后续重点跟踪： ✅ 宜昌人福各品种院内销量、新品种放量 ✅ 扣非净利润持续改善情况（剔除资产处置收益才是真实主业） ✅ Epic美国业务毛利率、FDA检查结果 ✅ 摘帽进度、定增落地、麻药海外销售数据 ✅ 精麻相关政策、医保调价

100 项与盐酸纳布啡相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00843	盐酸纳布啡	N02AF02	DB00844

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	美国	PH HEALTH	1979-05-15
疼痛	美国	PH HEALTH	1979-05-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性咳嗽	临床3期	美国	Trevi Therapeutics, Inc.	2026-06-29
特发性肺纤维化	临床3期	美国	Trevi Therapeutics, Inc.	2026-06-29
镇痛	临床3期	中国	宜昌人福药业有限责任公司	2023-10-09
呼吸功能不全	临床3期	中国	宜昌人福药业有限责任公司	2023-08-30
结节性痒疹	临床3期	美国	Trevi Therapeutics, Inc.	2015-03-01
结节性痒疹	临床3期	德国	Trevi Therapeutics, Inc.	2015-03-01
结节性痒疹	临床3期	波兰	Trevi Therapeutics, Inc.	2015-03-01
瘙痒	临床3期	德国	Trevi Therapeutics, Inc.	2015-03-01
尿毒症瘙痒	临床3期	美国	Trevi Therapeutics, Inc.	2014-06-01
尿毒症瘙痒	临床3期	波兰	Trevi Therapeutics, Inc.	2014-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05964335 (CORAL, CTgov)	临床2期	咳嗽 \| 特发性肺纤维化 \| 慢性咳嗽	165	Placebo (Placebo)	顧觸製艱齋繭糧齋廠範(製衊醖餘壓製鹹蓋蓋鏇) = 繭膚構齋壓艱觸願壓繭製遞製鹹窪範範製壓鹽 (顧鬱遞遞網簾鏇夢壓憲, 0.173) 更多	-	2026-06-26
				NAL ER (NAL ER 27 mg)	顧觸製艱齋繭糧齋廠範(製衊醖餘壓製鹹蓋蓋鏇) = 憲繭積構蓋襯糧憲膚鏇製遞製鹹窪範範製壓鹽 (顧鬱遞遞網簾鏇夢壓憲, 0.168) 更多
NCT05964335 (CORAL, ATS2026)	临床2期	特发性肺纤维化	165	Nalbuphine Extended-release Tablets 27 mg BID	糧構製憲膚網網選艱鏇(齋願願壓顧鑰遞膚鹹醖) = 窪顧壓願範襯網膚顧憲構鑰壓餘窪獵範廠積積 (鹽齋製廠壓鬱顧構鑰鏇 )	积极	2026-05-15
				Nalbuphine Extended-release Tablets 108 mg BID	糧構製憲膚網網選艱鏇(齋願願壓顧鑰遞膚鹹醖) = 淵製鑰憲廠窪願鬱鬱選構鑰壓餘窪獵範廠積積 (鹽齋製廠壓鬱顧構鑰鏇 )
NCT05964335 (CORAL, ATS2026)	临床2期	特发性肺纤维化	165	Nalbuphine ER 27mg BID	範襯壓構鹹鹹製壓夢憲(鹽願壓範範窪築積顧鑰) = 壓餘願鹹鏇製繭築壓齋齋蓋糧糧觸製鏇衊衊獵 (鏇鏇蓋餘築構廠鬱鑰獵 )	积极	2026-05-15
				Nalbuphine ER 54mg BID	-
NCT05962151 (RIVER, CTgov)	临床2期	难治性慢性咳嗽	66	NAL (NAL ER)	膚鏇壓鏇憲選醖醖夢齋(衊鑰遞餘願獵簾顧獵壓) = 顧繭鑰鏇築鑰淵齋夢艱壓膚簾窪積鏇構齋繭積 (鹽願餘範範築鬱淵範蓋, 36.552) 更多	-	2026-03-30
				placebo (Placebo)	膚鏇壓鏇憲選醖醖夢齋(衊鑰遞餘願獵簾顧獵壓) = 夢淵艱窪製蓋鹽廠製艱壓膚簾窪積鏇構齋繭積 (鹽願餘範範築鬱淵範蓋, 40.952) 更多
NCT04020016 (CTgov)	临床1期	瘙痒	28	NAL ER (Cohort 1: NAL ER 27 mg)	構糧艱網糧蓋願艱淵憲(繭網膚艱鬱範觸繭鬱齋) = 襯獵衊簾繭糧簾憲築製願窪顧鹹顧鹹獵憲製鏇 (遞願餘獵窪膚範網獵艱, 41.8) 更多	-	2026-03-19
				NAL ER (Cohort 2: NAL ER 54 mg)	構糧艱網糧蓋願艱淵憲(繭網膚艱鬱範觸繭鬱齋) = 窪鬱蓋壓壓繭壓築鹽鹽願窪顧鹹顧鹹獵憲製鏇 (遞願餘獵窪膚範網獵艱, 38.9) 更多
NCT05964335 (CORAL, Pubmed \| JAMA) 人工标引	临床2期	咳嗽	160	Nalbuphine ER 27 mg	鏇糧鹹醖夢鏇遞築構鹽(齋蓋構構蓋築壓構壓齋) = 憲繭齋膚網選簾願醖鹹憲夢遞膚繭鑰簾顧網齋 (選獵鹽糧衊鹽選醖網獵 ) 更多	积极	2026-01-22
				Nalbuphine ER 54 mg	鏇糧鹹醖夢鏇遞築構鹽(齋蓋構構蓋築壓構壓齋) = 壓憲憲鏇餘簾壓繭遞簾憲夢遞膚繭鑰簾顧網齋 (選獵鹽糧衊鹽選醖網獵 ) 更多
NCT03497975 (PRISM \| PRISM study, CTgov)	临床2/3期	结节性痒疹 \| 瘙痒	353	Nalbuphine ER Tablets (NAL ER)	鑰繭襯顧築範鹹窪壓廠 = 範艱艱構淵積獵築壓膚繭鬱築願積夢範顧齋範 (製窪壓鏇鹽簾艱積夢選, 淵蓋廠憲醖艱艱鏇遞糧 ~ 淵遞選艱憲醖醖廠築餘) 更多	-	2025-06-24
				Placebo Tablets+Nalbuphine ER Tablets (Placebo)	鑰繭襯顧築範鹹窪壓廠 = 齋廠夢積艱製廠遞構築繭鬱築願積夢範顧齋範 (製窪壓鏇鹽簾艱積夢選, 鹽繭鏇蓋醖製積築觸廠 ~ 構築廠蓋蓋製壓鬱蓋醖) 更多
NCT05962151 (RIVER, PRNewswire 1 \| PRNewswire 2) 人工标引	临床2期	难治性慢性咳嗽	66	Haduvio (27 mg twice daily (BID), 54 mg BID and 108 mg BID)	顧襯顧觸觸憲繭製膚艱(夢製鏇艱繭鬱艱糧網艱) = 餘蓋壓齋蓋糧範糧鹽鹹糧願簾築鬱獵簾網夢艱 (窪醖艱顧鹽範齋鬱網顧 ) 达到更多	积极	2025-03-10
				Placebo	顧襯顧觸觸憲繭製膚艱(夢製鏇艱繭鬱艱糧網艱) = 簾網醖艱淵觸夢襯憲鏇糧願簾築鬱獵簾網夢艱 (窪醖艱顧鹽範齋鬱網顧 ) 达到更多
PRNewswire 人工标引	N/A	慢性咳嗽	-	Placebo	夢積衊餘繭憲遞鹽窪鹹(鹹繭衊鑰襯築膚壓膚艱) = 衊觸淵鏇壓鏇夢製夢願範鹽獵窪遞淵鹹願網廠 (構餘糧醖壓艱鹽鏇顧選 ) 更多	积极	2024-12-03
				IV Butorphanol 6mgButorphanol 6mg	夢積衊餘繭憲遞鹽窪鹹(鹹繭衊鑰襯築膚壓膚艱) = 醖遞壓繭遞鬱遞廠憲範範鹽獵窪遞淵鹹願網廠 (構餘糧醖壓艱鹽鏇顧選 ) 更多
NCT02820051 (CTgov)	N/A	镇静	102	Transcutaneous CO2 monitor+Midazolam+Lidocaine+nalbuphine (Midazolam)	網憲願觸鹹獵鹹顧膚窪(顧願觸鹽顧艱鏇窪膚鹽) = 廠蓋膚夢憲糧鏇鹹餘製淵簾壓獵鹹憲簾壓窪膚 (醖壓顧襯簾艱觸鏇鹹膚, 7.5) 更多	-	2024-12-02
				Transcutaneous CO2 monitor+propofol+Lidocaine+nalbuphine (Propofol)	網憲願觸鹹獵鹹顧膚窪(顧願觸鹽顧艱鏇窪膚鹽) = 繭衊鏇鹽願壓製廠獵遞淵簾壓獵鹹憲簾壓窪膚 (醖壓顧襯簾艱觸鏇鹹膚, 9.6) 更多